The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Our Staff & Volunteers
    • The Antibody Society’s Standing Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Executive Committee
      • Finance & Audit Committee
      • Governance & Nominating Committee
      • Initiatives Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Biopharmaceutical Informatics Symposium
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2022
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2022
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Research Competitions
    • Science Writing Competition
      • Science Writing Competition Winners
    • Discount codes for meeting registration
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Jan Voskuil, PhD and Andrew Chalmers, PhD

Jan Voskuil, PhD and Andrew Chalmers, PhD

Speaker: Dr. Jan Voskuil has over thirty years accrued knowledge and experience in both academic and commercial environments on antibody and assay development. He set up the consultation and vending company Aeonian Biotech to deliver a new proprietary concept of selecting research antibodies from an increasingly complex market. Aeonian Biotech offers help to the relevant industries and to their customers to meet the quality requirements in the aftermath of recent international meetings on this subject. Dr. Voskuil has been the driving force behind the growth and quality of the Everest Biotech antibody catalogue, and an active expert member in discussions in relevant LinkedIn discussion groups. As Chief Scientific Officer, he was the direct contact for custom antibody services and for technical support and wrote all content in the technical support web pages of Everest Biotech. Dr. Voskuil is also active in the world of biomarkers. Through thorough reputation building, the company has transformed to a profit-generating enterprise with increasing frequency and amounts of dividends.

 

Speaker: Dr. Chalmers is a senior lecturer based at the University of Bath and one of the founders of CiteAb, the life science data company whose citation-based antibody search engine helps researchers from across the world find antibodies which are suitable for their experiments. He is also the lead scientific organizer of the International Antibody Validation Meeting series and a founding guest editor of the F1000Research Antibody Validation Channel. His research focuses on understanding the behavior of epithelial cells, with recent work investigating the role of stem cell regulators in prostate cancer.

 

Dr. Simon Goodman moderates this webinar series.

 

References from Dr. Voskuil:

  1. Voskuil JL. The challenges with the validation of research antibodies. F1000Res. 2017;6:161.
  2. Voskuil J. How difficult is the validation of clinical biomarkers? F1000Res. 2015;4:101.
  3. Voskuil J. Biomarkers and their dependence on well-reported antibodies. Per Med. 2015;12(6):545-8.
  4. Voskuil JLA. Commercial antibodies and their validation. F1000Res. 2014;3:232.

 

References from Dr. Chalmers:

  1. Helsby MA, Leader PM, Fenn JR, Gulsen T, Bryant C, Doughton G, et al. CiteAb: a searchable antibody database that ranks antibodies by the number of times they have been cited. BMC Cell Biol. 2014;15:6.
  2. Helsby MA, Fenn JR, Chalmers AD. Reporting research antibody use: how to increase experimental reproducibility. F1000Res. 2013;2:153.

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Thanks to all who participated in Antibody Engineering & Therapeutics Europe! June 9, 2022
  • European Commission approves Lunsumio for people with relapsed or refractory follicular lymphoma June 8, 2022
  • Join us on June 9th for our next webinar – Registration is open! May 26, 2022

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals